The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Angelo CastelloLuca ToschiSabrina RossiEmanuela MazziottiEgesta LopciPublished in: Journal of cancer research and clinical oncology (2020)
IMPI at the first restaging, combining both inflammatory and metabolic biomarkers, was correlated with PFS and OS. IMPI can be a potentially valuable tool for identifying NSCLC patients who are likely to benefit from ICI.